PURPOSE: MicroRNA (miRNA) expression profiles improve classification, diagnosis, and prognostic information of malignancies, including lung cancer. This study uncovered unique growth-suppressive miRNAs in lung cancer. EXPERIMENTAL DESIGN: miRNA arrays were done on normal lung tissues and adenocarcinomas from wild-type and proteasome degradation-resistant cyclin E transgenic mice to reveal repressed miRNAs in lung cancer. Real-time and semiquantitative reverse transcription-PCR as well as in situ hybridization assays validated these findings. Lung cancer cell lines were derived from each transgenic line (designated as ED-1 and ED-2 cells, respectively). Each highlighted miRNA was independently transfected into these cells. Growth-suppressive mechanisms were explored. Expression of a computationally predicted miRNA target was examined. These miRNAs were studied in a paired normal-malignant human lung tissue bank. RESULTS: miR-34c, miR-145, and miR-142-5p were repressed in transgenic lung cancers. Findings were confirmed by real-time and semiquantitative reverse transcription-PCR as well as in situ hybridization assays. Similar miRNA profiles occurred in human normal versus malignant lung tissues. Individual overexpression of miR-34c, miR-145, and miR-142-5p in ED-1 and ED-2 cells markedly repressed cell growth. Anti-miR cotransfections antagonized this inhibition. The miR-34c target, cyclin E, was repressed by miR-34c transfection and provided a mechanism for observed growth suppression. CONCLUSIONS: miR-34c, miR-145, and miR-142-5p were repressed in murine and human lung cancers. Transfection of each miRNA significantly repressed lung cancer cell growth. Thus, these miRNAs were growth suppressive and are proposed to exert antineoplastic effects in the lung.
PURPOSE: MicroRNA (miRNA) expression profiles improve classification, diagnosis, and prognostic information of malignancies, including lung cancer. This study uncovered unique growth-suppressive miRNAs in lung cancer. EXPERIMENTAL DESIGN: miRNA arrays were done on normal lung tissues and adenocarcinomas from wild-type and proteasome degradation-resistant cyclin E transgenic mice to reveal repressed miRNAs in lung cancer. Real-time and semiquantitative reverse transcription-PCR as well as in situ hybridization assays validated these findings. Lung cancer cell lines were derived from each transgenic line (designated as ED-1 and ED-2 cells, respectively). Each highlighted miRNA was independently transfected into these cells. Growth-suppressive mechanisms were explored. Expression of a computationally predicted miRNA target was examined. These miRNAs were studied in a paired normal-malignant human lung tissue bank. RESULTS:miR-34c, miR-145, and miR-142-5p were repressed in transgenic lung cancers. Findings were confirmed by real-time and semiquantitative reverse transcription-PCR as well as in situ hybridization assays. Similar miRNA profiles occurred in human normal versus malignant lung tissues. Individual overexpression of miR-34c, miR-145, and miR-142-5p in ED-1 and ED-2 cells markedly repressed cell growth. Anti-miR cotransfections antagonized this inhibition. The miR-34c target, cyclin E, was repressed by miR-34c transfection and provided a mechanism for observed growth suppression. CONCLUSIONS:miR-34c, miR-145, and miR-142-5p were repressed in murine and humanlung cancers. Transfection of each miRNA significantly repressed lung cancer cell growth. Thus, these miRNAs were growth suppressive and are proposed to exert antineoplastic effects in the lung.
Authors: James DiRenzo; Sabina Signoretti; Noriaki Nakamura; Ramon Rivera-Gonzalez; William Sellers; Massimo Loda; Myles Brown Journal: Cancer Res Date: 2002-01-01 Impact factor: 12.701
Authors: A I Saeed; V Sharov; J White; J Li; W Liang; N Bhagabati; J Braisted; M Klapa; T Currier; M Thiagarajan; A Sturn; M Snuffin; A Rezantsev; D Popov; A Ryltsov; E Kostukovich; I Borisovsky; Z Liu; A Vinsavich; V Trush; J Quackenbush Journal: Biotechniques Date: 2003-02 Impact factor: 1.993
Authors: Azra Krek; Dominic Grün; Matthew N Poy; Rachel Wolf; Lauren Rosenberg; Eric J Epstein; Philip MacMenamin; Isabelle da Piedade; Kristin C Gunsalus; Markus Stoffel; Nikolaus Rajewsky Journal: Nat Genet Date: 2005-04-03 Impact factor: 38.330
Authors: Jan Stenvang; Asli N Silahtaroglu; Morten Lindow; Joacim Elmen; Sakari Kauppinen Journal: Semin Cancer Biol Date: 2008-01-15 Impact factor: 15.707
Authors: Michael Z Michael; Susan M O' Connor; Nicholas G van Holst Pellekaan; Graeme P Young; Robert J James Journal: Mol Cancer Res Date: 2003-10 Impact factor: 5.852
Authors: Benjamin P Lewis; I-hung Shih; Matthew W Jones-Rhoades; David P Bartel; Christopher B Burge Journal: Cell Date: 2003-12-26 Impact factor: 41.582
Authors: Xi Liu; Lorenzo F Sempere; Yongli Guo; Murray Korc; Sakari Kauppinen; Sarah J Freemantle; Ethan Dmitrovsky Journal: Transl Res Date: 2011-02-04 Impact factor: 7.012
Authors: Fabrizio Galimberti; Sarah L Thompson; Xi Liu; Hua Li; Vincent Memoli; Simon R Green; James DiRenzo; Patricia Greninger; Sreenath V Sharma; Jeff Settleman; Duane A Compton; Ethan Dmitrovsky Journal: Clin Cancer Res Date: 2009-12-22 Impact factor: 12.531
Authors: Qing Feng; David Sekula; Yongli Guo; Xi Liu; Candice C Black; Fabrizio Galimberti; Sumit J Shah; Lorenzo F Sempere; Vincent Memoli; Jesper B Andersen; Bret A Hassel; Konstantin Dragnev; Ethan Dmitrovsky Journal: Mol Cancer Ther Date: 2008-12 Impact factor: 6.261
Authors: T Chiyomaru; H Enokida; S Tatarano; K Kawahara; Y Uchida; K Nishiyama; L Fujimura; N Kikkawa; N Seki; M Nakagawa Journal: Br J Cancer Date: 2010-02-16 Impact factor: 7.640
Authors: Stephen F Madden; Susan B Carpenter; Ian B Jeffery; Harry Björkbacka; Katherine A Fitzgerald; Luke A O'Neill; Desmond G Higgins Journal: BMC Bioinformatics Date: 2010-05-18 Impact factor: 3.169
Authors: Kelly C Heim; Joshua J Gamsby; Mary P Hever; Sarah J Freemantle; Jennifer J Loros; Jay C Dunlap; Michael J Spinella Journal: PLoS One Date: 2009-10-28 Impact factor: 3.240
Authors: Lea H Gregersen; Anders B Jacobsen; Lisa B Frankel; Jiayu Wen; Anders Krogh; Anders H Lund Journal: PLoS One Date: 2010-01-21 Impact factor: 3.240